Sustained Glycemic Outcomes with the MiniMed ™ 780G System: Real-World Evidence from >16,000 Users Across 18 Latin American Countries Over Two Years
Authors' conclusion
The MiniMed™ 780G AHCL system delivered consistent and durable glycemic control over 24 months across the full demographic and structural heterogeneity of Latin America. Performance was aligned with internationally recommended consensus targets and was independent of age, sex, country, and health care infrastructure.
Study context
- Population
- Individuals with T1D using the MiniMed 780G advanced hybrid closed-loop (AHCL) system, 18 Latin American countries, January 2020–October 2025; 27.1% pediatric (<16 years), 70.8% adult (≥16 years)1,204 in longitudinal sub-analysis
- Participants
- 16,669 individuals
- Exposure
- Overall vs ROS
- Overalln = 16,669
- Outcome
- TIR, time in tight range (TITR), GMI and TBR, stratified by age, sex, country and ROS
Methodological detailsmultinational, retrospective device data analysis, longitudinal sub-analysis
- Multinational
- Retrospective device data analysis
- Longitudinal sub-analysis
Main finding
As reported in the abstract
TIR, GMI and target attainment
| Group | Value | Mean glucose management indicator (GMI) | Time in range (TIR) > 70% attainment | Composite target (GMI < 7, TIR > 70, TB70 < 4, TB54 < 1) attainment | Mean TIR with ROS | Mean time in tight range (TITR) with ROS | TITR overall | TITR with ROS |
|---|---|---|---|---|---|---|---|---|
| Overall | mean 73.4% | 6.9% | ||||||
| ROS | mean 77.5% | 83.9% | 66.4% | |||||
| Pediatric | mean 70.0% | 74.2% | 51.2% | |||||
| Adult | mean 74.6% | 50.3% | 54.1% |
Value
Overallmean 73.4%
ROSmean 77.5%
Pediatricmean 70.0%
Adultmean 74.6%
Mean glucose management indicator (GMI)
Overall6.9%
ROS— not stated in the abstract
Pediatric— not stated in the abstract
Adult— not stated in the abstract
Time in range (TIR) > 70% attainment
Overall— not stated in the abstract
ROS83.9%
Pediatric— not stated in the abstract
Adult— not stated in the abstract
Composite target (GMI < 7, TIR > 70, TB70 < 4, TB54 < 1) attainment
Overall— not stated in the abstract
ROS66.4%
Pediatric— not stated in the abstract
Adult— not stated in the abstract
Mean TIR with ROS
Overall— not stated in the abstract
ROS— not stated in the abstract
Pediatric74.2%
Adult— not stated in the abstract
Mean time in tight range (TITR) with ROS
Overall— not stated in the abstract
ROS— not stated in the abstract
Pediatric51.2%
Adult— not stated in the abstract
TITR overall
Overall— not stated in the abstract
ROS— not stated in the abstract
Pediatric— not stated in the abstract
Adult50.3%
TITR with ROS
Overall— not stated in the abstract
ROS— not stated in the abstract
Pediatric— not stated in the abstract
Adult54.1%
- ROS adopted by users
- 19.2%
Observational data: associations, not effects.
Further findings
Durability of TIR (longitudinal sub-analysis) · 24 consecutive monthly time points
- TIR remained clinically stable within one and a half percentage points in both age groups
Original publication
Sustained Glycemic Outcomes with the MiniMed ™ 780G System: Real-World Evidence from >16,000 Users Across 18 Latin American Countries Over Two Years. Diabetes Technol Ther. Published 19 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →